Publications
2025
A Novel Toolkit of SARS-CoV-2 Sub-Genomic Replicons for Efficient Antiviral Screening
Erdmann, M., Wing, P. A. C., Webb, I., Kavanagh Williamson, M., Jearanaiwitayakul, T., Sullivan, E., . . . Davidson, A. D. (n.d.). A Novel Toolkit of SARS-CoV-2 Sub-Genomic Replicons for Efficient Antiviral Screening. Viruses, 17(5), 597. doi:10.3390/v17050597
Examining the feasibility of replacing ORF3a with fluorescent genes to construct SARS-CoV-2 reporter viruses.
Webb, I., Erdmann, M., Milligan, R., Savage, M., Matthews, D. A., & Davidson, A. D. (2025). Examining the feasibility of replacing ORF3a with fluorescent genes to construct SARS-CoV-2 reporter viruses.. The Journal of general virology, 106(2). doi:10.1099/jgv.0.002072
2024
SARS-CoV-2 infection enhancement by Amphotericin B: Implications for disease management
The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses.
Bigotti, M. G., Klein, K., Gan, E. S., Anastasina, M., Andersson, S., Vapalahti, O., . . . Yamauchi, Y. (2024). The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses.. Antiviral research, 224, 105837. doi:10.1016/j.antiviral.2024.105837
2023
SARS-CoV-2 NSP12 associates with TRiC and the P323L substitution acts as a host adaption.
Alruwaili, M., Armstrong, S., Prince, T., Erdmann, M., Matthews, D. A., Luu, L., . . . Hiscox, J. A. (2023). SARS-CoV-2 NSP12 associates with TRiC and the P323L substitution acts as a host adaption.. Journal of virology, 97(11), e0042423. doi:10.1128/jvi.00424-23
An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity.
Wing, P. A. C., Schmidt, N. M., Peters, R., Erdmann, M., Brown, R., Wang, H., . . . McKeating, J. A. (2023). An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity.. PLoS pathogens, 19(5), e1011323. doi:10.1371/journal.ppat.1011323
SARS-CoV-2 NSP12 associates with the TRiC complex and the P323L substitution is a host adaption
The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.
Goldswain, H., Dong, X., Penrice-Randal, R., Alruwaili, M., Shawli, G. T., Prince, T., . . . Hiscox, J. A. (2023). The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.. Genome biology, 24(1), 47. doi:10.1186/s13059-023-02881-5